

LOD/PREF/TT/FIP/395/2025-26

June 25, 2025

The Company Secretary,
Biogen Pharmachem Industries Ltd
Shop No. 8, First Floor, Makers - 1 Building,
Jawahar Road,, Rajkot, Gujarat, 360001

Re: Listing of 25,00,00,000 equity shares of Rs. 1/- each issued at a premium of Rs. 0.68/- bearing distinctive numbers from 652603001 to 902603000 issued to Non-promoters on preferential basis pursuant to conversion of warrants.

We acknowledge the receipt of your letter about the captioned matter, together with the enclosures and would advise that the Exchange is pleased to grant Listing approval to the listing application made by the company seeking permission for its aforesaid shares to be dealt in on the Exchange.

The Company should ensure compliance with the provisions of Regulation 167 of SEBI (ICDR) Regulations and as specified by SEBI from time to time.


Further, in case there is change exceeding two per cent of the total paid-up share capital of the company, the company shall file the shareholding pattern in XBRL mode as required under Regulations 31(1)(c) of SEBI LODR Regulations, 2015.

Please note that trading approval in the above-mentioned shares will be granted only after the company files with the Exchange:

- Listing approval from the National Stock Exchange of India Ltd. (if applicable) and
- Confirmation letters from NSDL/CDSL about crediting the above-mentioned shares to the respective beneficiary accounts/admitting the capital to the depository system. You are requested to file all such approvals together.
- Confirmation letters from NSDL/CDSL about lock-in of pre-preferential holding (if applicable)

In addition to above, the company should note that as per Schedule XIX of ICDR Regulations and as specified by SEBI vide SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, "Listed entities shall make an application for trading approval to the stock exchange/s within seven working days from the date of grant of listing approval by the stock exchange/s" along with the documents specified by stock exchange/s from time to time. Any Non-compliance with the above requirement will attract fine as mentioned in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

Yours faithfully,



Sabah Vaze
Assistant Vice President



Tejas Tandel
Deputy Manager